Details of the Drug
General Information of Drug (ID: DM1TNWG)
| Drug Name |
1-propionyl-1H-indole-2,3-dione
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
1-Propionyl-1H-indole-2,3-dione; 17529-69-0; 1-propanoyl-2,3-dihydro-1H-indole-2,3-dione; Propionylisatin; Isatin-based compound, 9; AC1LBV75; 1-propanoylindole-2,3-dione; CHEMBL386000; BDBM22789; MolPort-002-488-122; IHNYAHBLLCMRCD-UHFFFAOYSA-N; ZINC3086180; ZX-AN080727; ALBB-029917; AKOS001849000; 1-Propionyl-1H-indole-2,3-dione #; MCULE-1099895518; CCG-139392; 1H-Indole-2,3-dione, 1-(1-oxopropyl)-; EU-0084456; 1H-Isoindole-2,3(2H)-dione, 1-propionyl-; SR-01000512691
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 203.19 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 0.8 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 0 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


